Multiple Inflammatory Disease Opportunities
Ongoing Clinical Trials
NCT02443688 – Ongoing (Enrolling)
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of acebilustat Administered Orally Once-Daily for 48 Weeks in Adult Patients with Cystic Fibrosis.
Find out more about this trial at http://clinicaltrials.gov/show/NCT02443688.
Completed Clinical Trials
NCT01944735 – Completed
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose study to evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of acebilustat when Administered Orally to Cystic Fibrosis Patients for Fifteen Days.
Find out more about this trial at http://clinicaltrials.gov/show/NCT01944735.
NCT02233244 – Completed
A Phase 1, Open-Label, Two-Period, Fixed-Sequence, Drug-Drug Interaction Study to Evaluate the Pharmacokinetics and Safety of Acebilustat (formerly CTX 4430) and Midazolam in Healthy Adult Subjects.
Find out more about this trial at https://clinicaltrials.gov/ct2/show/NCT02233244.
NCT01748838 – Completed
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending Single- and Repeat-Dose Study of the Safety, Tolerability and Pharmacokinetics of acebilustat when Administered Orally to Healthy Adult Subjects with Two Single-Dose Groups Crossing over to Assess Food Effect.
Find out more about this trial at http://clinicaltrials.gov/show/NCT01748838.